MedPath

Dexmedetomidine as an Adjuvant for Sub-Tenon's Anesthesia

Phase 3
Completed
Conditions
Vitreoretinal Surgery Under Sub-Tenon's Anesthesia
Interventions
Registration Number
NCT02327156
Lead Sponsor
Magrabi Eye & Ear Hospital
Brief Summary

The investigator evaluated the motor and sensory block durations and the postoperative analgesic effects of adding dexmedetomidine to levobupivacaine for sub-Tenon's anesthesia in patients undergoing vitreoretinal surgery. Motor and sensory block durations were considered as a primary endpoint.

Detailed Description

Background: The investigator evaluated the motor and sensory block durations and the postoperative analgesic effects of adding dexmedetomidine to levobupivacaine for sub-Tenon's anesthesia in patients undergoing vitreoretinal surgery. Motor and sensory block durations were considered as a primary endpoint.

Methods: The investigator investigated 60 patients subjected to vitreoretinal surgery under sub-Tenon's anesthesia. The patients were randomly divided equally into 1 of 2 groups conferring to the local anesthesia (LA) solution used to receive either 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline (group L) or 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline (group LD). The total volume of the LA solution used was 5 mL. Motor block (akinesia) and sensory block durations were evaluated until the return of normal motor and sensory function. The sedation level was assessed during the surgery period and 24 hours postoperatively together with the degree of postoperative pain and the efficiency of postoperative analgesia. The sleep quality of the first postoperative night was assessed using the Consensus Sleep Diary (CSD).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria
  • incorporated patients younger than 18 years,
  • patients with a single eye,
  • history of sleep apnea,
  • severe cardiac disease, and
  • drug abuse or
  • if there was any contraindication to LA.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group LDdexmedetomidine4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
Primary Outcome Measures
NameTimeMethod
the motor and sensory block durationsparticipants will be followed for the duration of hospital stay, an expected average of 24 hours

expected to be extended in group LD

Secondary Outcome Measures
NameTimeMethod
sleep quality of the 1st postoperative night24 hours

improved the sleep quality

© Copyright 2025. All Rights Reserved by MedPath